Abstract 1732P
Background
Systemic therapy availability in Ukraine is fluid due to the war. This information is key to optimizing cancer care.
Methods
Online surveys assessing cancer treatment capacity were distributed to physicians in Ukraine through cancer-focused social media in April 2023. Results were analyzed with descriptive statistics and Fisher’s exact test.
Results
15 oncologists from 14 oncology centers and 12 hematologists from 9 hematology centers completed surveys, including 3 (25%) and 4 (27%), respectively, from the more war-affected Northern, Southern, and Eastern Ukraine. Of the 36 drugs used for solid tumors, limited availability (half of the time, rarely available, or unavailable) was reported for 11 (31%) drugs by 2-4 (14-29%) respondents: cisplatin, cyclophosphamide, doxorubicin, etoposide, fluorouracil, ifosfamide, methotrexate, vincristine, filgrastim, dexamethasone, tamoxifen. 7 (19%) had limited availability per 5-6 (36-42%): capecitabine, irinotecan, mesna, anastrozole, leuprolide, zoledronic acid, erlotinib. 12 (33%) drugs were limited per 7-8 (50-57%): abiraterone, bleomycin, carboplatin, docetaxel, gemcitabine, oxaliplatin, paclitaxel, vinblastine, vinorelbine, folinic acid, bicalutamide, trastuzumab. 7 (19%) were limited per 8-13 (57%-93%): nivolumab, diethylstilbestrol, bevacizumab, palbociclib, trastuzumab emtansine, sorafenib. Of 31 drugs used for hematologic malignancies, 4 (21%) were limited in availability per 2-4 respondents: vincristine, bortezomib, imatinib, azacitidine. 5 (16%) were limited per 5-6: bendamustine, filgrastim, doxorubicin, lenalidomide, hydroxycarbamide. 10 (32%) were reported to be limited by 7-8: rituximab, thalidomide, vinblastine, chlorambucil, bleomycin, methotrexate, daunorubicin, nilotinib. 10 (32%) were limited per 9-12: ibrutinib, mercaptopurine, eltrombopag, erythropoietin, thrombopoietin, ruxolitinib, venetoclax, brentuximab, gemtuzumab, obinutuzumab. Drug availability did not differ by country region (p > 0.05).
Conclusions
Shortages of essential anticancer drugs are a continued challenge in Ukraine during the war. Results are limited by small sample size and limited sampling from regions affected by active hostilities.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1757P - A real-world evaluation of the effectiveness of thermogram along with clinical breast examination in community-based breast cancer screening program
Presenter: Rahul Ravind
Session: Poster session 23
1758P - Body composition meets precision medicine: The prognostic value of sarcopenia in patients (pt) treated with Molecularly Targeted Agents (MTA)
Presenter: Cinta Hierro
Session: Poster session 23
1760P - Systematic review of quality of life (QoL) inclusion among endpoints, reporting and impact of QoL results in phase III non-inferiority trials of systemic treatments in oncology
Presenter: Jessica Paparo
Session: Poster session 23
1761P - Incidence of herpes zoster in cancer patients in Europe: A systematic review
Presenter: Inga Posiuniene
Session: Poster session 23
1762P - Are published data up-to-date? Analysis of time to publication in major oncological journals
Presenter: Pawel Sobczuk
Session: Poster session 23
1763P - The challenge for Cancer Trials Ireland (CTI) to sponsor NCI and non-EU sponsored trials in the EU
Presenter: Eibhlin Mulroe
Session: Poster session 23
1886P - Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)
Presenter: Craig Gedye
Session: Poster session 23
1887P - Adjuvant everolimus (EVE) in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology: Results from the phase III SWOG S0931 (EVEREST) trial
Presenter: Primo Lara
Session: Poster session 23
1888P - 24-month follow up of durvalumab and savolitinib combination in MET-driven clear cell and non-clear cell renal cancer
Presenter: Francesca Jackson-Spence
Session: Poster session 23